We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $141M
1-Year Est. Return 190.82%
This Fund
S&P 500
This Quarter Est. Return
+11.38%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$82.1M
AUM Growth
+$21.9M
Cap. Flow
+$50.3M
Cap. Flow %
61.24%
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
–
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
JBIO
Jade Biosciences
JBIO
+$51.9M

Top Sells

Rank Stock Value
1
CTNM
Contineum Therapeutics
CTNM
+$1.63M
2
TPST icon
Tempest Therapeutics
TPST
+$7

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GLUE icon
1
Monte Rosa Therapeutics
GLUE
$1.83B
$25.5M 31.04%
5,652,922
– –
CRSP icon
2
CRISPR Therapeutics
CRSP
$4.66B
$24.2M 29.52%
498,558
– –
JBIO
3
Jade Biosciences
JBIO
$1.16B
$15.2M 18.56%
+1,525,820
New +$51.9M
SKYE icon
4
Skye Bioscience
SKYE
$21.2M
$8.39M 10.22%
2,007,704
– –
RPTX
5
DELISTED
Repare Therapeutics
RPTX
$3.68M 4.48%
2,646,657
– –
CTNM
6
Contineum Therapeutics
CTNM
$528M
$2.15M 2.62%
542,628
-375,535
-41% -$1.63M
TPST icon
7
Tempest Therapeutics
TPST
$14M
$1.83M 2.23%
269,772
-1
-0% -$7
ADVM
8
DELISTED
Adverum Biotechnologies
ADVM
$1.09M 1.33%
506,821
– –

Similar funds

POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
RB
Renasant Bank Tupelo, Mississippi $141M AUM 16.9% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
CFGW
Chancellor Financial Group WB Wilkes-Barre, Pennsylvania $141M AUM 23.22% 1-Year Est. Return

Versant Venture Management's Q2 2025 Portfolio in Review

As of Q2 2025, Versant Venture Management held 8 positions worth $82.1M, up 36% from $60.2M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management deployed $50.3M of net new capital in Q2 2025, opening 1 new position. Its largest new stake was Jade Biosciences: 1,525,820 shares worth $15.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Contineum Therapeutics, an estimated $1.63M trimmed.

  • Versant Venture Management's largest Q2 2025 buy was Jade Biosciences: 1,525,820 shares worth $15.2M.
  • Versant Venture Management's biggest Q2 2025 reduction was Contineum Therapeutics, cutting an estimated $1.63M.
  • Versant Venture Management's ten largest holdings make up 100% of its $82.1M portfolio in Q2 2025.
  • Versant Venture Management opened 1 new position and closed 0 in Q2 2025.
  • Versant Venture Management's portfolio value rose 36% quarter-over-quarter to $82.1M.

Based on Versant Venture Management's 13F filing for Q2 2025, filed 11 Aug 2025.